Literature DB >> 24182705

Monoclonal gammopathy-associated proliferative glomerulonephritis.

Sanjeev Sethi1, S Vincent Rajkumar.   

Abstract

Monoclonal gammopathy is characterized by circulating monoclonal immunoglobulin owing to clonal proliferation of immunoglobulin-producing B lymphocytes or plasma cells. Clonal proliferation of B lymphocytes is seen in B-cell lymphoma/leukemia, and clonal plasma cell proliferation is seen in multiple myeloma and monoclonal gammopathy of undetermined significance. The monoclonal immunoglobulin in the setting of a B-cell or plasma cell disorder can cause a proliferative glomerulonephritis via 2 mechanisms: (1) glomerular deposition of the monoclonal immunoglobulin with activation of the classical pathway of complement (direct mechanism), resulting in an immunoglobulin-positive C3-positive glomerulonephritis, and (2) glomerular deposition of complement factors of the alternative and terminal pathway via inhibition of alternative pathway-regulating proteins by the monoclonal immunoglobulin (indirect mechanism), resulting in immunoglobulin-negative C3-positive glomerulonephritis (C3 glomerulopathy). Evaluation should include serum and urine electrophoresis and immunofixation as well as serum-free light-chain assay. If a monoclonal immunoglobulin is detected on these tests, bone marrow biopsy or imaging is needed to exclude more advanced plasma cell dyscrasia. Evaluation of alternative pathway of complement should be done in patients with Ig-negative C3-positive glomerulonephritis. If monoclonal gammopathy is due to an underlying malignant disease such as myeloma, lymphoma, or chronic lymphocytic leukemia, then specific treatment should be aimed at treating the malignant disease, with the goal of eradicating the clonal cells producing the immunoglobulin. In contrast, if monoclonal gammopathy is due to a monoclonal gammopathy of undetermined significance, treatment options include bortezomib, cyclophosphamide, and dexamethasone for a non-IgM monoclonal immunoglobulin and rituximab alone or in combination with cyclophosphamide and dexamethasone for an IgM monoclonal immunoglobulin.
Copyright © 2013 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  C3 glomerulonephritis; C3GN; CLL; DDD; MGUS; VCD; bortezomib, cyclophosphamide, and dexamethasone; chronic lymphocytic leukemia; dense deposit disease; monoclonal gammopathy of undetermined significance

Mesh:

Substances:

Year:  2013        PMID: 24182705     DOI: 10.1016/j.mayocp.2013.08.002

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  24 in total

1.  Mayo Clinic/Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of GN.

Authors:  Sanjeev Sethi; Mark Haas; Glen S Markowitz; Vivette D D'Agati; Helmut G Rennke; J Charles Jennette; Ingeborg M Bajema; Charles E Alpers; Anthony Chang; Lynn D Cornell; Fernando G Cosio; Agnes B Fogo; Richard J Glassock; Sundaram Hariharan; Neeraja Kambham; Donna J Lager; Nelson Leung; Michael Mengel; Karl A Nath; Ian S Roberts; Brad H Rovin; Surya V Seshan; Richard J H Smith; Patrick D Walker; Christopher G Winearls; Gerald B Appel; Mariam P Alexander; Daniel C Cattran; Carmen Avila Casado; H Terence Cook; An S De Vriese; Jai Radhakrishnan; Lorraine C Racusen; Pierre Ronco; Fernando C Fervenza
Journal:  J Am Soc Nephrol       Date:  2015-11-13       Impact factor: 10.121

Review 2.  The Complexity and Heterogeneity of Monoclonal Immunoglobulin-Associated Renal Diseases.

Authors:  Sanjeev Sethi; S Vincent Rajkumar; Vivette D D'Agati
Journal:  J Am Soc Nephrol       Date:  2018-04-27       Impact factor: 10.121

3.  C3 glomerulonephritis and autoimmune disease: more than a fortuitous association?

Authors:  Mariam P Alexander; Fernando C Fervenza; An S De Vriese; Richard J H Smith; Samih H Nasr; Lynn D Cornell; Loren P Herrera Hernandez; Yuzhou Zhang; Sanjeev Sethi
Journal:  J Nephrol       Date:  2015-07-18       Impact factor: 3.902

Review 4.  Reclassification of membranoproliferative glomerulonephritis: Identification of a new GN: C3GN.

Authors:  Maurizio Salvadori; Giuseppina Rosso
Journal:  World J Nephrol       Date:  2016-07-06

Review 5.  How I manage monoclonal gammopathy of undetermined significance.

Authors:  Ronald S Go; S Vincent Rajkumar
Journal:  Blood       Date:  2017-11-28       Impact factor: 22.113

Review 6.  [Diagnosis and treatment of kidney involvement in plasma cell diseases : Renal involvement in multiple myeloma and monoclonal gammopathies].

Authors:  V Gödecke; J J Schmidt; J H Bräsen; C Koenecke; H Haller
Journal:  Internist (Berl)       Date:  2019-01       Impact factor: 0.743

7.  Acute kidney injury due to thrombotic microangiopathy in a patient with primary Sjögren's syndrome.

Authors:  Yi Wang; Xun Zhou; Xiaoyan Ma; Xinyu Yang; Yishu Wang; Min Tao; Binbin Cui; Tianyu Xiao; Shougang Zhuang; Na Liu
Journal:  Ren Fail       Date:  2022-12       Impact factor: 3.222

8.  C3 glomerulopathy associated with monoclonal Ig is a distinct subtype.

Authors:  Aishwarya Ravindran; Fernando C Fervenza; Richard J H Smith; Sanjeev Sethi
Journal:  Kidney Int       Date:  2018-05-03       Impact factor: 10.612

9.  IgD heavy-chain deposition disease: detection by laser microdissection and mass spectrometry.

Authors:  Virginie Royal; Patrick Quint; Martine Leblanc; Richard LeBlanc; Garrett F Duncanson; Robert L Perrizo; Fernando C Fervenza; Paul Kurtin; Sanjeev Sethi
Journal:  J Am Soc Nephrol       Date:  2014-09-05       Impact factor: 10.121

10.  Audit of the Prevalence of Noncorrelation of Immunofixation with Protein Electrophoresis and Serum Free Light Chain Assays in Multiple Myeloma in a Tertiary Cancer Care Center.

Authors:  Chandramallika Paul; Subhosmito Chakraborty; S Sugumar; Ranjan Bhattacharya; Sandip Rath; Sarit Chakraborty
Journal:  Indian J Clin Biochem       Date:  2020-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.